Methoxamine is an alpha-adrenergic drug, its unique pharmacokinetics and mechanism of action on alpha-1 receptors lead to consider it, similarly to phenylephrine, as a ®rst-choice drug for treating drug-induced or veno-occlusive priapism. The experience obtained with its use in the management of three cases of priapism lasting over 7 h and one case of sustained rigid erection caused during anesthetic induction are reported.
Introduction
Since the introduction of intracavernous injections of vasoactive drugs in clinical practice, the incidence of priapism have enormously increased, from being an occasional ®nding 1 to be the most common cause of priapism, according to Lue. 2 The incidence of this untoward effect of intracavernous injections depends on the drug used, the dose administered and the underlying etiology of impotence. In a review of the literature, 3 papaverine induced priapism in 9.5% of 2314 patients, the combination of papaverine plus phentolamine in 5.3% of 2914 patients and PGE1 only in 2.4% of the 1284 patients revised. These values refer to priapism occurring as a result of initial diagnostic tests, while only 0.4% occurred during the period of therapy with self-injections at home, in which the appropriate dose for each patient is already known. Regarding the etiology of impotence, it is recommended to administer low doses of vasoactive drugs when neurologic or psychogenic causes are suspected since the hemodynamics of erection is intact.
In most cases, drug-induced priapism can be resolved through the action of alpha-adrenergic substances, also administered directly to the corpora cavernosa of the penis. The ef®cacy of this treatment will depend on the duration of this drug-induced priapism. In the initial phase, when hypoxia and acidosis are present, contractility of smooth muscle is depressed but may respond to high doses of adrenergic agents. In a later phase, cell ischemia and ®brosis takes place, making the smooth muscle irresponsive to pharmacologic agents.
In this present study we report on the ef®cacy and safety of methoxamine, a selective alpha-1 adrenergic agent, in the treatment of drug-induced priapism.
Case reports

Case 1
A 44 y old male presented to the urology department complaining of erectile dysfunction in the last year, with low-quality erections which prevented penetration, night erections were present, but without complete rigidity, he was a moderate smoker and had no other diseases referred. Physical examination was normal and also blood biochemistry and hormone laboratory tests. Penile Color Doppler ultrasound with intracavernous injection (ICI) of PGE1 at dose of 20 mcg was performed. Prior to this procedure, the patient required admission to the psychiatry department due to a maniac crisis in relation to a manic-depressive psychosis, an underlying condition that he had not reported in the clinical history. The response to ICI was immediate, and a good arterial¯ow (peak systolic velocity of 35 cm/sg) with an apparently normal venous competence (end-diastolic velocity of 1 cm/sg) was seen. Seven hours after the ICI, the psychiatry department consulted the staff urologist due to a sustained erection with complete and painful rigidity.
The patient was initially managed by anesthetizing the base of the penis and with aspirating the corpora cavernosa, obtaining a quite¯uid blood ¯ow. Nevertheless, a complete detumescence was not achieved and the erection recurred, so methoxamine was intracavernosally administered (4 cc of the solution of a 20 mg ampoule in 10 cc saline). After this, the rigidity disappeared in less than 5 min. Blood pressure and heart rate were monitored and no changes were registered.
Case 2
A 54 y old male attended the emergency room complaining of a sustained, painful erection starting 18 h before. He denied any history of known neurological, cardiovascular or systemic diseases. He was a smoker of 20 cigarettes/d and moderate alcohol consumption. He had multiple sexual relations with no stable partner. On admission, he reported to have been treated for several months for erectile dysfunction at another center, where he received intracavernous self-injections. (He did not know the type of drug or the exact dose.) On his own, the patient had increased the dose prescribed, which caused a persistent, rigid erection the day before, the presence of pain led the patient to attend the emergency room.
Aspiration of corpora cavernosa showed the presence of viscous blood and saline¯ushing was ineffective. Therefore, ICI with methoxamine was then performed (2 cc of the solution of a 20 mg ampoule in 10 cc saline). Erection resolved within 10 min, with complete detumescence and no changes in blood pressure or heart rate.
Case 3
A 63 y old male reported impotence starting 2 y before, with erections of reduced rigidity and short duration, but preserved libido and ejaculation. Clinical history included moderate smoking and L4±L5 disk hernia surgically treated 2 y before. Physical examination was normal and laboratory tests showed normal parameters. As part of the study, Color Doppler ultrasound of the cavernous arteries was performed with ICI of PGE1 20 mcg, which showed a good arterial in¯ow. The clinical response was a good erection with signi®cant rigidity. On the following visit, the patient reported that this erection had persisted for 5 h, and ®nally subsided spontaneously. With a diagnosis of erectile dysfunction of probable neurological origin, training for self-injection started with only 5 mcg of PGE1 in order to assess the response to this dose.
Eight hours later, the patient was admitted to the emergency room presenting a rigid, painful erection in the absence of any sexual stimulus. After failed aspiration and¯ushing of the corpora cavernosa with saline, an intracavernous injection of methoxamine was given, diluting 20 mg in 10 ml of saline and injecting 5 ml of this solution. The erection disappeared within one minute and blood pressure and heart rate remained unchanged.
Case 4
A 35 y old male with no relevant personal history, was admitted for internal urethrotomy of an urethral stenosis under general anesthesia. The patient developed a rigid erection, lasting over 30 min, which prevented us to perform the urethroscopy. An ICI of methoxamine was administered (2 cc of the solution of a 20 mg ampoule in 10 cc saline). The erection subsided immediately, monitoring of heart rate and blood pressure showed no signi®cant changes.
Discussion
Phenylnephrine is usually considered the ®rst-choice drug for pharmacologic priapism.
4±6 This would be justi®ed by its proven ef®cacy, 4 as a result of its potent alpha-adrenergic activity, along with its minimal activity on beta-1 and beta-2 receptors, which would minimize the risks of systemic side effects. However, due to the very few indications for its use, this drug is not easily available in some countries.
Other drugs, such as ethylephrine, epinephrine, norepinephrine and metaraminol, have also been used as an effective therapy in priapism. The dosage of some of these drugs are shown in Table 1 . Nevertheless, their higher af®nity for beta-1 receptors may cause adverse effects, such as hypertensive crises or acute pulmonary edema. In fact, two deaths due to the intracavernous use of metaraminol have been reported. 7 Epinephrine does not seem to be the drug of choice for this condition either, due of its intense beta-agonist effects, leading to a direct cardiotonic effects. Furthermore, the capacity of this latter substance to achieve penile detumescence is not better than that attributed to phenylephrine.
On the other hand, methoxamine, or beta-hydroxybeta-(2,5 dimethoxyphenyl)-isopropylamine, is a sympathomimetic substance which has, as phenyl- Intracavernous methoxamine in the treatment of priapism J Jara et al ephrine, virtually only af®nity for alpha-1 receptors. Its main effect, when injected by IR or IM route is a blood pressure increase, which is totally due to peripherally-induced vasoconstriction. When injected directly into the blood stream, this drug, like phenylephrine, stimulates minimally heart betareceptors. Additionally, it causes little or no central nervous system (CNS) stimulation. 8 In Spain it is normally available as methoxamine hydrochloride in a 20 mg/ml solution.
Methoxamine, after its intracavernous injection activates alpha-1 post-synaptic receptors. Its action is exerted through protein Gp, to which these receptors are bound, this protein, in turn, stimulates phospholipase C and causes the transformation of inositol diphosphate to inositol triphosphate plus diaglycerol. These two substances can increase the bioavailability of intracellular calcium in the smooth muscle cell which activates the kinase of the myosin light chain, promoting its sliding over actin. This mechanism leads to the contraction of the muscular cell, terminating, therefore, the sustained relaxation state that caused priapism.
This action can be achieved even in long-term priapism, as seen in case report 1. Some authors do not consider drug-induced priapism as true priapism, and report these cases as`prolonged erections', assuming that they have a different outcome, without hypoxia and no tissue acidosis or ®brosis, since many of them are self-limited. However, a recent study on erections induced by vasoactive drugs lasting over 24 h 9 reported that these erections behave as any other low-¯ow`true priapism' of a similar duration, leading to ischemic changes and ®brosis if left untreated for enough time.
Intraoperative tumescence also entails a con¯ict-ing problem if transurethral endoscopic surgery is to be performed. Among the great variety of therapeutic options discussed to resolve this intraoperative complication, the use of vasodilators such as amyl nitrite has been mentioned, but its poor action and potential side effects in the elderly advise against its use. Other measures with a doubtful ef®cacy, such as irrigation of the perineum with cold water or the application of ethyl chloride on the glans penis to achieve a vasoconstrictive effect due to cold, have been ®nally rejected after documenting the ef®cacy and safety of the intracavernous injection of alpha-1 adrenergic agents.
Staerman 6 reported on the treatment of 23 cases of intraoperative erection during penile or endoscopic surgery, which were successfully resolved with an injection of 0.2 mg phenylephrine. The hemodynamic changes evidenced, a transient increase in blood pressure, were not important even in the elderly. The use of methoxamine for this purpose has been reported previously in our country in one case of erection after spinal blockage with tetracaine, which subsided with no local or systemic side effects. 10 Therefore, it seems that this intraoperative complication, which appears to be more common in patients aged under 50 y, under general anesthesia with propofol or epidural anesthesia, can be currently treated safely with intracavernous injections of these agents, as shown in one of our cases.
There is no clear data, in the literature, regarding the dose of methoxamine for its intracavernous administration. However, it is well known that methoxamine can be administered at doses of 10± 20 mg for intramuscular injection. 8 Assuming this, we have observed that 4±10 mg is an effective dose, with no side effects. After diluting an ampoule (20 mg) in 10 ml of saline, 2±5 ml (2/1000 solution) are utilized. We use a 25 G insulin needle, or the butter¯y needle (14±16 G) used for the previous aspiration and¯ushing, as described in the cases reported in this paper.
Conclusion
In our experience, methoxamine is a highly safe and effective drug for inducing penile detumescence, achieving the resolution of long-term priapism without adverse side effect.
